Search results
Results from the WOW.Com Content Network
Example of uses, and other notes 7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use 7 days of Ara-C plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) Acute myelogenous leukemia, excluding acute promyelocytic leukemia: ABVD
As an example, the incidence of congestive heart failure is 4.7%, 26% and 48% respectively when patients received doxorubicin at 400 mg/m 2, 550 mg/m 2 and 700 mg/m 2. [4] Therefore, the lifetime cumulative doxorubicin exposure is limited to 400–450 mg/m 2 in order to reduce congestive heart failure incidence to less than 5%, although ...
Currently, there are four main anthracyclines in medical use: Doxorubicin; Daunorubicin (doxorubicin precursor) Epirubicin (a doxorubicin stereoisomer) Idarubicin (a daunorubicin derivative) [17] Idarubicin is able to pass through cell membranes easier than daunorubicin and doxorubicin because it possesses less polar subunits, making it more ...
Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. [2] Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. [2] It is administered by injection into a vein. [2]
Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. [10] This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. [10] It is often used together with other chemotherapy agents. [10] Doxorubicin is given by injection into a vein. [10]
Idarubicin / ˌ aɪ d ə ˈ r uː b ɪ s ɪ n / or 4-demethoxydaunorubicin is an anthracycline antileukemic drug.It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II.
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP.. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...